Vitiligo
☆ AI Dermatology — Free Service
Dalam keputusan Stiftung Warentest 2022 dari Jerman, kepuasan pengguna terhadap ModelDerm hanya lebih rendah sedikit berbanding dengan perundingan teleperubatan berbayar.
Dalam keputusan Stiftung Warentest 2022 dari Jerman, kepuasan pengguna terhadap ModelDerm hanya lebih rendah sedikit berbanding dengan perundingan teleperubatan berbayar.
Vitiligo jari adalah lebih sukar untuk dirawat daripada kawasan lain. Selain daripada kosmetik yang tidak sedap dipandang, vitiligo adalah normal dan tidak berjangkit. Dalam bidang dermatologi, rawatan yang paling berkesan ialah rawatan fototerapi atau laser (excimer) 2-3 kali seminggu selama sekurang-kurangnya 1 tahun. Jika anda tidak boleh kerap ke hospital atas sebab kewangan atau kerana sibuk, anda boleh mencuba mesin fototerapi yang diluluskan untuk kegunaan di rumah.
vitiligo kelopak mata
Vitiligo di tangan
relevance score : -100.0%
ReferencesVitiligo ialah gangguan kulit yang biasa, menyebabkan tompok kulit putih akibat kehilangan melanosit. Penyelidikan terkini menunjukkan ia merupakan penyakit autoimun. Walaupun sering dianggap isu kosmetik, vitiligo boleh menjejaskan kesejahteraan mental dan aktiviti harian. Pada tahun 2011, pakar mengklasifikasikan jenis yang dipanggil segmental vitiligo secara berasingan daripada jenis lain.
Vitiligo is a common skin disorder that causes patches of white skin due to the loss of melanocytes. Recent research shows it's an autoimmune disease. While it's often seen as a cosmetic issue, it can deeply affect mental well-being and daily life. In 2011, experts classified a type called segmental vitiligo separately from others.
Vitiligo is a common skin disorder that causes patches of white skin due to the loss of melanocytes. Recent research shows it's an autoimmune disease. While it's often seen as a cosmetic issue, it can deeply affect mental well-being and daily life. In 2011, experts classified a type called segmental vitiligo separately from others.
Pesakit vitiligo aktif mempunyai beberapa pilihan terapi, seperti glukokortikoid sistemik, fototerapi, dan imunosupresan sistemik. Pesakit vitiligo yang stabil mungkin mendapat kelegaan daripada kortikosteroid topikal, perencat kalsineurin topikal, fototerapi, dan prosedur pemindahan kulit. Kemajuan terkini dalam memahami proses asas vitiligo telah membawa kepada pembangunan terapi yang disasarkan. Pada masa ini, perencat JAK merupakan pilihan yang paling menjanjikan, menawarkan toleransi yang baik dan hasil yang berfungsi, walaupun terdapat risiko mengaktifkan jangkitan terpendam serta kesan sampingan sistemik yang biasa dengan agen imunosupresif lain. Penyelidikan berterusan bertujuan untuk mengenal pasti sitokin utama yang terlibat dalam perkembangan vitiligo (IFN-γ, CXCL10, CXCR3, HSP70i, IL-15, IL-17/23, TNF). Menyekat sitokin ini telah menunjukkan harapan dalam model haiwan dan pada beberapa pesakit. Selain itu, siasatan terhadap miRNA‑based therapeutics dan adoptive Treg cell therapy sedang dijalankan.
Current models of treatment for vitiligo are often nonspecific and general. Various therapy options are available for active vitiligo patients, including systemic glucocorticoids, phototherapy, and systemic immunosuppressants. While stable vitiligo patients may benefit from topical corticosteroids, topical calcineurin inhibitors, phototherapy, as well as transplantation procedures. Recently, a better understanding of the pathophysiological processes of vitiligo led to the advent of novel targeted therapies. To date, JAK inhibitors are the only category that has been proved to have a good tolerability profile and functional outcomes in vitiligo treatment, even though the risk of activation of latent infection and systemic side effects still existed, like other immunosuppressive agents. Research is in progress to investigate the important cytokines involved in the pathogenesis of vitiligo, including IFN-γ, CXCL10, CXCR3, HSP70i, IL-15, IL-17/23, and TNF, the blockade of which has undergone preliminary attempts in animal models and some patients. In addition, studies on miRNA-based therapeutics as well as adoptive Treg cell therapy are still primary, and more studies are necessary.
Current models of treatment for vitiligo are often nonspecific and general. Various therapy options are available for active vitiligo patients, including systemic glucocorticoids, phototherapy, and systemic immunosuppressants. While stable vitiligo patients may benefit from topical corticosteroids, topical calcineurin inhibitors, phototherapy, as well as transplantation procedures. Recently, a better understanding of the pathophysiological processes of vitiligo led to the advent of novel targeted therapies. To date, JAK inhibitors are the only category that has been proved to have a good tolerability profile and functional outcomes in vitiligo treatment, even though the risk of activation of latent infection and systemic side effects still existed, like other immunosuppressive agents. Research is in progress to investigate the important cytokines involved in the pathogenesis of vitiligo, including IFN-γ, CXCL10, CXCR3, HSP70i, IL-15, IL-17/23, and TNF, the blockade of which has undergone preliminary attempts in animal models and some patients. In addition, studies on miRNA-based therapeutics as well as adoptive Treg cell therapy are still primary, and more studies are necessary.
Tiada ubat yang terbukti berkesan untuk vitiligo. Bagi mereka yang berkulit cerah, penggunaan pelindung matahari dan solekan biasanya disyorkan. Pilihan rawatan lain mungkin termasuk krim steroid atau fototerapi.
○ Rawatan
#Phototherapy
#Excimer laser
#Tacrolimus ointment